Heart failure & cardiomyopathies
Intravenous Iron Therapy for Heart Failure and Iron Deficiency: An Updated Meta-Analysis of Randomized Clinical Trials
Pooled result · First HHF or CV mortalityResult — go to the resultOdds ratio 0.73 95% CI 0.58–0.92Authors' conclusion
In patients with HF and iron deficiency, IV iron therapy reduced the incidence of composite of first HHF or CV mortality.
Study context
- Population
- Patients with heart failure (HF) and iron deficiency
- Participants
- 6,651 patients14 randomized controlled trials (RCTs)
- Comparison
- Intravenous (IV) iron vs placebo or standard of care
- Outcome
- Composite of:
- First HF hospitalisation (HHF)
- CV mortality
Methodological detailsrandom-effects model, Search of PubMed/MEDLINE, Embase and Cochrane Library to 15 September 2023
- Random-effects model
- Search of PubMed/MEDLINE, Embase and Cochrane Library to 15 September 2023
Pooled result
First HHF or CV mortality
Odds ratio
0.73
95% CI 0.58–0.92
IV ironvs Control
OR 0.73 (95% CI 0.58–0.92)
As reported in the abstract
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| CV mortalityTrend | 0.88 (0.76–1.01) | |
| All-cause mortality · 1 yearTrend | 0.85 (0.71–1.02) | |
| First HHFTrend | 0.73 (0.51–1.05) | |
| 0.512Odds ratio (log scale) |
| Outcome | MD (95% CI) | |
|---|---|---|
| LVEFTrend | 4.54 (−0.13 to 9.21) | |
| −50510Difference (linear scale) |
Meta-regression: baseline left ventricular ejection fraction (LVEF) on first HHF or cardiovascular (CV) death
- Significant inverse moderating effect of baseline LVEF
Original publication
Intravenous Iron Therapy for Heart Failure and Iron Deficiency: An Updated Meta-Analysis of Randomized Clinical Trials. ESC Heart Fail. Published 4 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →